DAVA Oncology shared a post on X:
“Dr. Sandip Patel at DAVA Lung highlights the role of full genomic profiling in Stage IV NSCLC. For EGFR mutations: osimertinib, chemo-osimertinib, or amivantamab+lazertinib. Future strategies may hinge on molecular risk and balancing patient burden.”
More posts featuring DAVA Oncology.
